<img src="https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce?size=2" nborder="0" align="left" hspace="5" vspace="5" title="logo.jpg" alt="Genmab A/S"/>Company Announcement COPENHAGEN, Denmark; May 29, 2026 – <a href="https://www.globenewswire.com/Tracker?data=P6X3vrp7LdSc3FPt8GUxQ8dBCZuyqMRREqKOaLJFemYjk20E_qahR8NAZXWTTYcS5d8_nAPg9_9MYhRRrefwkQ==" rel="nofollow" target="_blank" title="">Genmab A/S</a> (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. About Genmab  Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=P6X3vrp7LdSc3FPt8GUxQ4bUB0LOXbAHfYMleY446cvcBpAFc4LFGythlN_ulm2VOXZNlc_tUH3jTKSN80oKJHMr2fuoVIIz88QMVE1GZ7XNBLh_94ZByEhsFZg28Scn-eLrpBcayR-7XZbzTHTwBN4mcZHkQ8JqMl3aj2-NEyOAn4nEpSJypo4O2yOBcU0-DRuDssXJZbzmtYiycTcfgCJViPpCS4X8gc1dUbTHs_0=" rel="nofollow" target="_blank" title="Genmab.com">Genmab.com</a> and follow us on <a href="https://www.globenewswire.com/Tracker?data=fm0i_YMx2MbUThJjMow1rLW-w0hTlxhJ-c1-ke13KhwoNXWTRajpR-dUcYPgZYKiRWUTKMHIcImsPzQQNM4ZiPa5SEjdP-cePs7mwcXH_T8=" rel="nofollow" target="_blank" title="LinkedIn">LinkedIn</a> and <a href="https://www.globenewswire.com/Tracker?data=VDgxIfQiG96aDPlxz2bPeeD_bqgVL_z7NaU8btsdyZp9I5vd4n_r1vsvoGFFEXXmXPKluMzqqal2MMJiZfKCLA==" rel="nofollow" target="_blank" title="X">X</a>. Contact:         Marisol Peron, Senior Vice President, Global Communications &amp; Corporate Affairs T: +1 609 524 0065; E: <a href="https://www.globenewswire.com/Tracker?data=niRzsIBpnKpRg1LFrrY2teQL_2yb1M2EYQtLI73ThHJ0_bqSEv_s2kT_YmgTWZAAlGbvzR4CH39Ietb4bCpjNA==" rel="nofollow" target="_blank" title="mmp@genmab.com">mmp@genmab.com</a> Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: <a href="https://www.globenewswire.com/Tracker?data=EOPGwVGQ9ITrrGIM4ZEUokp5L6Pqu_d-ZXkQJhoKoW3gL0ZzXctmORv1MA5k17EZLyORBxDvgD5dDRYGBIDorw==" rel="nofollow" target="_blank" title="acn@genmab.com">acn@genmab.com</a> The Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on <a href="https://www.globenewswire.com/Tracker?data=8V7EfkaS6kjyFJ58Ndgxd6GHZOMq77NnB-OXdYx9mQKBT3kWxe-O-xpcXxVoGFzHmaeRj4EEMOjE2P9iO-M-FMKpmQn2XffVi2hWiAb7Djs=" rel="nofollow" target="_blank" title="">www.genmab.com</a> and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at <a href="https://www.globenewswire.com/Tracker?data=8V7EfkaS6kjyFJ58Ndgxd-mffX_mbBVgtyJS99LLbokAD--GfR1xqlC9kEfgpN-TP_HVLoc-B6pB1P8Xm-sLS9r7ZcJ_tVAcX_U6n0Na-MU=" rel="nofollow" target="_blank" title="">www.sec.gov</a>. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 Genmab A/S Carl Jacobsens Vej 30 2500 Valby Denmark 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://www.globenewswire.com/Tracker?data=K_s91gGpHdmdXhA4iDQCqazcfBRKm1iEvFuul6X7eR3UQMxCCDB1XI1tZI--stHdGhBewAmLOtngTBE4JWHaEaDRk-Cve0X6Ifq06-FiA0NWwflLg8jWsTZdEHWzb_hEWz_1IPtXmat_zhy5SRHN8EFFfLk6kccIovm3l4l_H8lPVyhRa2eabctDmRnWyTXfscKK-OsbB9O7978CbjOcCA==" title="290526_CA28_Managerial Employee Transactions" rel="nofollow">290526_CA28_Managerial Employee Transactions</a>
 </li>
 </ul>
 <img alt="" src='https://ml-eu.globenewswire.com/media/YWM0NmJmZDQtNDQyMy00YWQ4LWEzZDUtNzIwMGE4ODc2ZTBhLTEwMTMyNDEtMjAyNi0wNS0yOS1lbg==/tiny/Genmab-A-S.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn